Laurimer Kuilan-Torres

FDA investigator · also recorded as Opr Ous Laurimer Kuilan-Torres

Appears on 16 documents from 2015 to 2025, most often at sites in Puerto Rico. Most often cites production record review (21 CFR 211.192).

16
Documents on file
5.2
Observations per 483
2015
First seen
2025
Most recent

What they cite most

From 82 observations

Activity by year

2015: 2, 2016: 2, 2017: 2, 2018: 2, 2019: 2, 2022: 1, 2023: 1, 2024: 2, 2025: 2

Where

Puerto Rico 5 · China 2 · North Carolina 2 · Texas 2 · Arizona 1 · Czech Republic 1

Is Laurimer Kuilan-Torres coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

16 documents, newest first
FirmOpen
483 Aurolife Pharma LLCApr 10, 2025 · Durham, North Carolina
483 Aurige Pharma LLCMar 24, 2025 · Durham, North Carolina
483 Pharmalogic Austin LLCNov 21, 2024 · Austin, Texas
483 Simtra US LLCFeb 20, 2024 · Bloomington, Indiana
483 Novo Nordisk A/SNov 7, 2023 · Hilleroed, Denmark
483 Smith & Nephew Wound ManagementSep 30, 2022 · Fort Worth, Texas
483 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (FDF site)Jun 13, 2019 · Lianyungang, China

About this profile

What does Laurimer Kuilan-Torres inspect?

Laurimer Kuilan-Torres appears on 16 documents on file covering 14 sites, most often in Puerto Rico.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.22 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Laurimer Kuilan-Torres is dated Apr 10, 2025.